Publication | Closed Access

The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB

InflammationCardiovascular DiseaseMedicineDpp-4 Inhibitor SaxagliptinPhysiologyImmunologyVascular PharmacologyEndothelial DysfunctionLipid PeroxidationVascular BiologyLipoprotein MetabolismPharmacologyCell SignalingOx-ldl-induced Endothelial DysfunctionOxidative Stress